Novozymatic SRL
Novozymatic reported total assets of 148,440 € at the end of the 2025 financial year (annual accounts filed with the NBB on 06 Jul 2026).
The score of Novozymatic shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Total assets +81 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Novozymatic's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −98,442 € | ||||
| Equity | −352,246 € | ||||
| Cash | 26,593 € | ||||
| EBITDA | −56,284 € | ||||
| Total assets | 148,440 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 06 Jul 2026
- Year ended 31 Dec 2024filed on 22 Jul 2025
- Year ended 31 Dec 2023filed on 08 Jul 2024
- Year ended 31 Dec 2022filed on 06 Jul 2023
- Year ended 31 Dec 2021filed on 04 Jul 2022
Novozymatic's financial analysis
- Solvency-237.3%sector median: 56.0%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Novozymatic
Novozymatic's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0761.771.979
- VAT number
- BE0761771979
- Peppol
- Registered · 0208:0761771979 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 19 Jan 2021
- Registered office
- 2950 Kapellen
- Latest accounts
- 2025 · filed on 06 Jul 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Novozymatic (SRL) has been based in Kapellen since 2021, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net loss of 98,442 € and equity of −352,246 €; its revenue is not published. Its solvency stands at -237.3%, below the median of its sector (56.0%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Novozymatic
Companies in the same business, of comparable size and area, outside its group.
- APR Pharma Manufacture of basic pharmaceutical products Courcelles · balance sheet 244,955 €
- GRNR Invest Manufacture of basic pharmaceutical products Zemst · balance sheet €2.26m
- NO Headache Manufacture of basic pharmaceutical products Uccle · balance sheet 261,728 €
- SpectronRx Europe Manufacture of basic pharmaceutical products Grimbergen · balance sheet 198,933 €
- Yaro Preclinical Consulting Manufacture of basic pharmaceutical products Turnhout · balance sheet 158,481 €
- G²VH Impact Activities of holding companies Boutersem · balance sheet 128,601 €
- Harika Lifij Manufacture of basic pharmaceutical products Evere · balance sheet 105,370 €
- Apo Kuipers Retail sale of pharmaceutical products Lubbeek · balance sheet 146,357 €
Frequently asked questions about Novozymatic
What is the revenue of Novozymatic?
Novozymatic files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Novozymatic?
In Belgium, the VAT number is the company number prefixed with BE: BE0761771979 for Novozymatic, if the company is VAT-registered. Its company number (CBE) is 0761.771.979.
Where is the registered office of Novozymatic?
According to the CBE register, the registered office of Novozymatic is in 2950 Kapellen.
What is the equity of Novozymatic?
At the close of the 2025 financial year, the equity of Novozymatic amounts to -352,246 €, a solvency of -237.3% of total assets.
Who manages Novozymatic?
The register lists 2 active mandates at Novozymatic. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Novozymatic
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →